Barr Pharmaceuticals
 |
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (September 2008) |
 |
|
| Industry | Pharmaceuticals & Medical Devices |
|---|---|
| Founded | New York (1970) |
| Headquarters | Montvale, NJ, USA |
| Key people | Bruce Downey, CEO |
| Products | Generic and Proprietary Pharmaceuticals |
| Revenue | Over $1 Billion USD fiscal year 2005 |
| Employees | 2000 |
Barr Pharmaceuticals was a global specialty pharmaceutical company that operated in more than 30 countries worldwide. Barr were engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients.
[edit] History
Barr Laboratories, Inc. was founded in 1970 by Edwin A. Cohen and was ultimately taken public under his leadership.
On July 18, 2008, it was announced that rival firm, Teva Pharmaceutical Industries Ltd, would acquire Barr Pharmaceuticals Inc for $7.46 billion plus the assumption of net debt of approximately $1.5 billion.[1] Today Barr Laboratories exists only as a sub-division of Teva Pharmaceuticals, as part of the Teva Active Pharmaceutical Ingredients (TAPI) division.
Teva Pharmaceuticals develops and markets generic pharmaceuticals under various brand names, including the Barr Laboratories, Inc. label. Teva Pharmaceuticals is the largest generic drug manufacturer in the world.
[edit] References
- ^ Staff (2008-07-21), "Teva Coughs Up $7.46B for Barr Reinforcing Its Number One Spot in the Generics Market", Genetic Engineering & Biotechnology News, GEN News Highlights (Mary Ann Liebert), ISSN 1937-8661, http://www.genengnews.com/news/bnitem.aspx?name=38938670, retrieved 2008-09-26
